105
Participants
Start Date
August 10, 2016
Primary Completion Date
December 13, 2017
Study Completion Date
December 27, 2017
Nebulized Sodium Nitrite
Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
Placebo
Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
Stony Brook University Medical Center, Stony Brook
Abington Memorial Hospital, Abington
University of Pennsylvania Health System, Philadelphia
Jefferson Medical College, Philadelphia
Johns Hopkins Hospital, Baltimore
Duke University Medical Center, Durham
Emory University School of Medicine, Atlanta
University Hospitals Cleveland Medical Center, Cleveland
Metro Health System, Cleveland
Cleveland Clinic Foundation, Cleveland
Mayo Clinic, Rochester
Northwestern University, Chicago
V.A St. Louis Health Care System, St Louis
Washington University School of Medicine, St Louis
University of Missouri Health System, Columbia
Tufts Medical Center, Boston
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Boston V.A. Healthcare System, West Roxbury
The University of Vermont - Fletcher Allen Health Care, Burlington
Collaborators (2)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Aires Pharmaceuticals, Inc.
INDUSTRY
University of Vermont
OTHER
Université de Montréal
OTHER
Mayo Clinic
OTHER
Massachusetts General Hospital
OTHER
Adrian Hernandez
OTHER